Hi Kayla,

Thank you for allowing us to re-run our samples on the HT plate. Could you please confirm whether you will be running all 5,000 targets on our samples, or just the ~2,000 targets that are in the HT panel but not the 3072 panel?

We would like to exclude the samples in wells E11 (Sample ID SM-N8JR) F11 (Sample ID SM-N8JRG), G11 (SM-N8JRS), and H11 (Sample ID SM-N8JS5) from being run on the HT plate. Please let me know if there is any other information you need before re-running these samples.

With regards to our internal controls, we rely heavily on the fractionation pattern observed in different targets. For example, we expect to see a peak in fractions 9 and 10 for EV-associated proteins such as tetraspanins (CD63 in the 3072 OLINK panel), and a peak in fractions 13-15 for soluble proteins such as EPCAM. Before submitting our samples, we analyzed them using a previously validated SIMOA assay to confirm the fractionation pattern of CD81, a different tetraspanin that has been proven to be EV-associated and reliably displays the correct fractionation pattern.

We also look at the CVs of all the targets, though we place particular emphasis on the variation in results of targets that were run in multiple panels. Ideally, there would be minimal variation across these targets, which is why we were concerned when the CV for TNF-alpha was so high.

Best,

Sydney